Palantir Just Hit a Record High. What's the Smart Move Now?
The tech company's revenue growth rate accelerated in Q1.
Palantir's commercial business in the U.S. is seeing explosive growth.
The stock's wild valuation leaves no room for error.
10 stocks we like better than Palantir Technologies ›
Data and artificial intelligence company Palantir (NASDAQ: PLTR) seemed to defy gravity in 2024. Shares more than quadrupled, rising a staggering 340%. With such an incredible rise, you'd be forgiven for guessing that the stock would cool off in 2025. But, so far, the opposite is true. Shares are heating up, rising by more than 105% year to date as of this writing. This has given the tech stock a gain of approximately 800% since the start of 2024.
With shares trading at record highs. What should investors do? Does it make sense to buy more shares and hope the momentum continues? Or should investors take a more cautious approach and hold or even sell the stock?
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »
Soaring sales
One thing Palantir really has going for it is its top-line growth. The tech company posted first-quarter revenue of $884 million, up 39% year over year. Highlighting the company's momentum, this was an acceleration from 36% year-over-year growth in the previous quarter.
Fueling Palantir's first quarter of 2025 was 55% year-over-year growth in U.S. revenue. Accounting for $628 million of the quarter's total revenue, the U.S. market is vital for Palantir. Supporting this market was a 71% year-over-year increase in commercial revenue and a 45% jump in government revenue.
Zooming out to all of the company's markets, Palantir said in its first-quarter update that it closed 139 deals worth $1 million or greater, 51 deals worth at least $5 million, and 31 deals worth $10 million or more.
With these strong results now behind it, management had the confidence to raise full-year revenue guidance. The company said it now expects 2025 revenue to be between $3.890 billion and $3.902 billion. This compares to revenue of about $2.9 billion in 2024. The midpoint of management's 2025 revenue guidance range, therefore, assumes about 36% growth.
This impressive top-line growth is bolstering profits. Palantir's first-quarter net income was approximately $214 million, more than double its profit of about $106 million in the year-ago quarter.
Comments from Palantir co-founder and CEO Alexander Karp in the company's first-quarter earnings call suggest he believes the company is still in its early innings.
"We are in the middle of a tectonic shift in the adoption of our software, particularly in the U.S..." Karp noted. "We are delivering the operating system for the modern enterprise in the era of AI."
A valuation problem
While Palantir's top-line momentum is certainly impressive, there's one big problem for investors: The market seems to have already priced in more rapid growth for years to come.
Today, Palantir's market capitalization sits at about $365 billion -- more than 93 times the high end of management's guidance range for full-year 2025 revenue. Using the company's trailing-12-month sales, Palantir currently has a price-to-sales ratio of 123. This would be a high figure even for a price-to- earnings ratio.
And what is Palantir's price-to-earnings ratio? It's 672. Yes, you heard that right.
It's safe to say that investors have already bid up the stock to a level that prices in the most optimistic assumptions for this company.
So, what should investors do? The decision is a personal one -- one that you'll have to make on your own. However, if I owned the stock, I'd sell. And for those who don't own shares, I'd avoid them like the plague at this price. Of course, I could be wrong. It's always possible that Palantir exceeds even my most bullish assumptions. Still, I believe there are likely better places with less risk and greater upside potential for investors to allocate their capital.
Palantir is a great company. But expectations are simply too high. Investors would be wise to wait to see if they can buy shares at a better entry price.
Should you invest $1,000 in Palantir Technologies right now?
Before you buy stock in Palantir Technologies, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!*
Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of July 15, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 minutes ago
- Globe and Mail
U.S. Department of Justice to Sponsor Cellebrite for FedRAMP ATO
TYSONS CORNER, Va., July 23, 2025 (GLOBE NEWSWIRE) -- Cellebrite (NASDAQ: CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced the U.S. Department of Justice (DOJ) will serve as the official sponsoring agency for the platform's pursuit of a FedRAMP High authorization. Cellebrite announced its intent to pursue FedRAMP authorization in 2024. In 2025, Cellebrite Government Cloud (CGC) was reviewed by a Third-Party Assessment Organization (3PAO), and the FedRAMP Program Management Office (PMO) prepared a Readiness Assessment Report (RAR), which granted Cellebrite Government Cloud FedRAMP High Ready status. DOJ's sponsorship is the critical step required for Cellebrite Government Cloud (CGC) to advance from its current FedRAMP High Ready designation to 'In Process' status. This marks a major milestone that significantly accelerates Cellebrite's compliance journey towards a full Authorization to Operate (ATO). 'We are proud to offer our U.S. federal customers reliable, secure and cutting-edge cloud solutions that enhance their investigative processes and expedite their missions,' said Erik Sachwitz, General Manager of Cellebrite Federal Solutions, Inc. 'We are grateful to the Justice Department for entrusting us to implement their workflow on the Cellebrite Government Cloud. This milestone marks a significant advancement to our ongoing efforts to deepen our support of U.S. federal agencies.' The Cellebrite Government Cloud (CGC) will launch with a comprehensive suite of digital investigative tools. The initial offering provides U.S. federal agencies secure access to two of the company's market-leading solutions: Cellebrite Inseyets, enabling immediate online access to Cellebrite's latest digital forensics capabilities, and Cellebrite Guardian, for collaborative digital evidence review, sharing and storage. Together, these integrated solutions are designed to deliver greater operational efficiencies, support end-to-end collaboration and strengthen the overall chain of custody to help U.S. federal agencies advance their missions while meeting the scalability and security requirements of national, regional and local public safety customers. By shifting digital investigation workflows to the cloud, agencies and attorneys gain secure, flexible access to evidence from anywhere, while also harnessing advanced analytical capabilities enabled by powerful cloud infrastructure. Demonstrating a commitment to supporting diverse missions and operational environments, Cellebrite ensures agencies will continue to have access to on-premises, hybrid and fully offline solutions, empowering them to operate effectively regardless of their unique requirements. References to Websites and Social Media Platforms References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release. About Cellebrite Cellebrite's (Nasdaq: CLBT) mission is to enable its global customers to protect and save lives by enhancing digital investigations and intelligence gathering to accelerate justice in communities around the world. Cellebrite's AI-powered Digital Investigation Platform enables customers to lawfully access, collect, analyze and share digital evidence in legally sanctioned investigations while preserving data privacy. Thousands of public safety organizations, intelligence agencies, and businesses rely on Cellebrite's digital forensic and investigative solutions—available via cloud, on-premises, and hybrid deployments—to close cases faster and safeguard communities. To learn more, visit us at and find us on social media @Cellebrite. Caution Regarding Forward Looking Statements This document includes 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the United States Private Securities Litigation Reform Act of 1995. Forward looking statements may be identified by the use of words such as 'forecast,' 'intend,' 'seek,' 'target,' 'anticipate,' 'will,' 'appear,' 'approximate,' 'foresee,' 'might,' 'possible,' 'potential,' 'believe,' 'could,' 'predict,' 'should,' 'could,' 'continue,' 'expect,' 'estimate,' 'may,' 'plan,' 'outlook,' 'future' and 'project' and other similar expressions that predict, project or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include, but are not limited to, this marks a major milestone that significantly accelerates Cellebrite's compliance journey towards a full Authorization to Operate (ATO); and we are proud to offer our U.S. federal customers reliable, secure and cutting-edge cloud solutions that enhance their investigative processes and expedite their missions are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to: Cellebrite's ability to continue advancing its FedRAMP activities to achieve full FedRAMP authorization in a timely manner; Cellebrite's ability to keep pace with technological advances and evolving industry standards; Cellebrite's material dependence on the purchase, acceptance and use of its solutions by law enforcement and government agencies; real or perceived errors, failures, defects or bugs in Cellebrite's DI solutions; Cellebrite's failure to maintain the productivity of sales and marketing personnel, including relating to hiring, integrating and retaining personnel; intense competition in all of Cellebrite's markets; the inadvertent or deliberate misuse of Cellebrite's solutions; failure to manage its growth effectively; Cellebrite's ability to introduce new solutions and add-ons; Cellebrite's dependency on its customers renewing their subscriptions and purchasing new subscriptions; the low volume of business Cellebrite conducts via e-commerce; risks associated with the use of artificial intelligence; the risk of requiring additional capital to support the growth of its business; risks associated with Cellebrite's dependency on third parties for supplying components or services and with higher costs or unavailability of materials used to create its hardware product components; fluctuations in foreign currency exchange rates; lengthy sales cycle for some of Cellebrite's solutions; near term declines in new or renewed agreements; risks associated with inability to recruit, train and retain qualified personnel and senior management; the security of Cellebrite's operations and the integrity of its software solutions against cyber-attacks, information technology system breaches or disruptions; risks associated with the negative publicity related to Cellebrite's business and use of its products; risks related to Cellebrite's intellectual property; the regulatory constraints to which Cellebrite is subject; risks associated with Cellebrite's operations in Israel, including the ongoing Israel-Hamas war, the increased tension between Israel and Iran and its proxies, including the ongoing hostilities between Israel and Hezbollah, and the risk of a greater regional conflict; risks associated with different corporate governance requirements applicable to Israeli companies and risks associated with being a foreign private issuer and an emerging growth company; market volatility in the price of Cellebrite's shares; changing tax laws and regulations; risks associated with joint, ventures, partnerships and strategic initiatives; risks associated with Cellebrite's significant international operations, including due to fluctuations in foreign currency exchange rates, rising global inflation and exposure to regions subject to political or economic instability; risks associated with Cellebrite's failure to comply with anti-corruption, trade compliance, anti-money-laundering and economic sanctions laws and regulations; risks relating to the adequacy of Cellebrite's existing systems, processes, policies, procedures, internal controls and personnel for Cellebrite's current and future operations and reporting needs; and other factors, risks and uncertainties set forth in the section titled 'Risk Factors' in Cellebrite's annual report on Form 20-F filed with the SEC on March 18, 2025, and in other documents filed by Cellebrite with the U.S. Securities and Exchange Commission ('SEC'), which are available free of charge at You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, in this communication or elsewhere. Cellebrite undertakes no obligation to update its forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. Media Victor Cooper Sr. Director of Corporate Communications + Content Operations +1 404.510.2823 Investor Relations Andrew Kramer Vice President, Investor Relations investors@ +1 973.206.7760
Globe and Mail
2 minutes ago
- Globe and Mail
Transcat to Host First Quarter Fiscal Year 2026 Conference Call and Webcast on Thursday, August 7, 2025 at 11:00 a.m. Eastern Time
Transcat, Inc. (Nasdaq: TRNS) ('Transcat' or the 'Company'), a leader in test measurement, control and calibration, announced that it will release its first quarter fiscal year 2026 results after the close of financial markets on Wednesday, August 6, 2025. The Company will host a conference call and webcast on Thursday, August 7, 2025 at 11:00 a.m. ET to review the financial and operating results for the period and discuss its corporate strategy and outlook. A question-and-answer session will follow. First Quarter Fiscal Year 2026 Conference Call Thursday, August 7, 2025 11:00 a.m. Eastern Time Dial-in – Toll-Free US / Canada: (800) 267-6316 Dial-in – Toll / International: (203) 518-9783 Conference ID: TRANSCAT (THIS CONFERENCE ID WILL BE REQUIRED FOR ENTRY) Webcast and accompanying slide presentation: A telephonic replay will be available from 3:00 p.m. ET on the day of the conference call through Thursday, August 14, 2025. To listen to the archived call, dial (844) 512-2921 from the US or Canada, or (412) 317-6671 from international locations, and enter conference ID number 11159645 or access the webcast replay at where a transcript will be posted once available. About Transcat Transcat, Inc. is a leading provider of accredited calibration, reliability, maintenance optimization, quality and compliance, validation, Computerized Maintenance Management System (CMMS), and pipette services. The Company is focused on providing best-in-class services and products to highly regulated industries, particularly the Life Science industry, which includes pharmaceutical, biotechnology, medical device, and other FDA-regulated businesses, as well as aerospace and defense, and energy and utilities. Transcat provides periodic on-site services, mobile calibration services, pickup and delivery, in-house services at its 33 Calibration Service Centers strategically located across the United States, Puerto Rico, Canada, and Ireland. Inclusive of customer embedded locations and other field offices, we operate out of more than 50 locations. The breadth and depth of measurement parameters addressed by Transcat's ISO/IEC 17025 scopes of accreditation are believed to be the best in the industry. Transcat also operates as a leading value-added distributor that markets, sells, and rents new and used national and proprietary brand instruments to customers primarily in North America. The Company believes its combined Service and Distribution segment offerings, experience, technical expertise, and integrity creates a unique and compelling value proposition for its customers. Transcat's strategy is to leverage its strong brand and unique value proposition that includes its comprehensive instrument service capabilities, enterprise asset management, and leading distribution platform to drive organic sales growth. The Company will also look to expand its addressable calibration market through acquisitions and capability investments to further realize the inherent leverage of its business model. More information about Transcat can be found at:
National Post
2 minutes ago
- National Post
Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
Article content Article content CAMBRIDGE, Mass. — Enveric Biosciences (NASDAQ: ENVB) ('Enveric' or the 'Company'), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced a second Notice of Allowance from the United States Patent and Trademark Office (USPTO) for novel compounds within its EVM401 Series, expanding its intellectual property assets in the treatment of mental health disorders. Article content The allowed patent application, titled 'Substituted N-Propylamine Fused Heterocyclic Mescaline Derivatives,' covers a unique series of methylone-inspired compounds, which are structurally differentiated benzodioxole derivatives engineered as non-hallucinogenic modulators of neurotransmitters relevant for neuropsychiatric disorders. Article content 'With this second patent allowance for the EVM401 Series, Enveric continues to strengthen its position as a first-in-class developer of neuroplastogenic small-molecule therapeutics,' said Joseph Tucker, Ph.D., Director and CEO of Enveric. 'These patent-protected molecules are designed to capture the desirable neuroplasticity-promoting effects of methylone, while offering novel chemical structures that enable both strong IP protection and a potential path to repeat-dose outpatient care.' Article content Enveric's molecules share pharmacophoric elements with methylone, an MDMA analog recently associated with positive Phase 2 results for post-traumatic stress disorder (PTSD), but differ structurally in ways that render them patentable and proprietary. In contrast, methylone, a synthetic cathinone with structural limitations, has no available composition of matter patent exclusivity because its structure is in the public domain. Article content Enveric's differentiated benzodioxole analogs may offer similar therapeutic promise while potentially enabling a clearer regulatory and commercial path. The Company expects further preclinical testing will be required to evaluate safety, pharmacokinetics, and functional activity against PTSD and other psychiatric endpoints. Article content 'The expansion of the EVM401 Series reflects Enveric's commitment to developing a deep pipeline of next-generation, non-hallucinogenic neuroplastogens that align with the scalability and safety needs of modern mental health treatment,' added Dr. Tucker. 'We believe this patent further positions Enveric at the forefront of the development of a new wave of targeted, accessible neuroplastogenic small-molecule drugs' Article content About Enveric Biosciences Article content Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders. Leveraging its unique discovery and development Psybrary™ platform, which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications, Enveric seeks to develop a robust intellectual property portfolio of novel drug candidates. Enveric's lead molecule, EB-003, is a potential first-in-class neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering from difficult-to-address mental health disorders. Enveric is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing other novel, patented Psybrary™ platform drug candidates to third-party licensees advancing non-competitive market strategies for patient care. Enveric is headquartered in Naples, FL with offices in Cambridge, MA and Calgary, AB Canada. For more information, please visit Article content Forward-Looking Statements Article content This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as 'plans,' 'expects' or 'does not expect,' 'proposes,' 'budgets,' 'explores,' 'schedules,' 'seeks,' 'estimates,' 'forecasts,' 'intends,' 'anticipates' or 'does not anticipate,' or 'believes,' or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize and submit its IND filing to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric's products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively. Article content A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric's filings with the Securities and Exchange Commission, including Enveric's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Article content Article content Article content Article content Contacts
